Coloplast

A POSTIVE DANISH INFLEXION

06/06/25 -"As a tiny country fighting for its place on the planet, Denmark has always been an interesting anchor to review market trends.  The following chart, looking at the AlphaValue Danish coverage ..."

PDF page sample
Pages
65
Language
English
Published on
06/06/25
Download
You may also be interested by these reports :
10/06/25
Due to the weaker performance in China and the US, which together account for over 35% of sales, we have revised our estimates downwards. However, we ...
06/06/25
At the outset, and at a risk of repeating ourselves, Coloplast (BUY; Denmark) is a top-tier MedTech play. A fact validated by a top quartile position ...
06/06/25
We have updated our estimates, incorporating the latest figures. We now anticipate increased profitability, driven by the enhanced effectiveness of ...
04/06/25
Despite the challenges outlined in the EPS section, which have led to a significant reduction in our target price, we continue to strongly recommend ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO